Cempra’s Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cempra’s Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases

— Both pivotal Phase 3 studies now published in leading infectious disease journals —

— FDA and EMA currently reviewing marketing applications for solithromycin for CABP in U.S. and EU —

CHAPEL HILL, N.C., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP ), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the publication of its pivotal Phase 3 study, SOLITAIRE-IV, comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for the treatment of community-acquired bacterial pneumonia (CABP) in Clinical Infectious Diseases .

As previously reported, the SOLITAIRE-IV study demonstrated that solithromycin was non-inferior to moxifloxacin, a potent respiratory fluoroquinolone, for treatment of CABP, meeting its primary endpoint that was aligned with FDA guidance.

Cempra’s other pivotal Phase 3 study with solithromycin, SOLITAIRE-ORAL, which evaluated the efficacy and safety of oral solithromycin versus oral moxifloxacin for the treatment of CABP, also met its primary non-inferiority endpoint and was published in Lancet Infectious Diseases in February 2016.

“The SOLITAIRE-IV study highlights the potential for physicians to transition CABP patients from IV to oral solithromycin, without needing to add or change drug classes. This type of approach could have significant clinical and public health benefits,” said Thomas M. File, M.D., from Northeast Ohio Medical University and lead author of the study.

“If approved, solithromycin may help address the urgent problem of antibiotic resistance and provide physicians with a new, potent macrolide monotherapy option that currently does not exist when treating patients with CABP,” File added.

According to the U.S. Centers for Disease Control and Prevention (CDC), CABP is the leading cause of death due to infectious disease in the United States, killing more than 53,000 people annually. Streptococcus pneumoniae ( S. pneumoniae ) is the leading cause of bacterial pneumonia in the U.S. and drug-resistant S. pneumoniae is responsible for 1.2 million infections a year, according to the CDC.

“Both of Cempra’s Phase 3 pivotal trials with solithromycin met their primary endpoint and we are pleased that both studies have now been published by two of the leading infectious disease journals in the world,” said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra.

“We believe these studies provide strong data supporting the safety and efficacy associated with solithromycin and we look forward to our ongoing interactions with regulators to achieve approval for this important new antibiotic, which could help to address the growing problem of antibiotic resistance,” Fernandes added.

About Solithromycin

Solithromycin is a highly potent next-generation macrolide which has activity against most macrolide-resistant CABP pathogens. In vitro and in vivo studies have shown potent activity against S. pneumoniae as well as an extended spectrum of activity against community-acquired methicillin-resistant S. aureus (CA-MRSA), streptococci, haemophilus, enterococci, Mycobacterium avium and in animal models of malaria. It is also active against atypical bacteria, such as legionella, chlamydia, mycoplasma and ureaplasma, and against gonococci and other organisms that cause genitourinary tract infections. It is eight to 16 times more potent than azithromycin against many bacteria and is active against azithromycin-resistant strains. The activity of solithromycin against resistant strains is driven by its ability to interact with three sites on the bacterial ribosome, compared to the single binding site of first- and second-generation macrolides.

About Community-Acquired Bacterial Pneumonia

Community-acquired bacterial pneumonia (CABP) is the number one cause of death from an infection, particularly in the very young and in the elderly. CABP is one of the most commonly diagnosed bacterial infections in the U.S. with five to 10 million cases per year. Although many strains of the primary CABP pathogen,  Streptococcus pneumoniae ,  are resistant to currently-approved macrolides, this class of antibiotic remains among the most commonly prescribed antibacterial drugs for CABP in both hospital and community settings. Due to the rising threat of microbial resistance, along with concerns over antibiotic tolerability and impact on intestinal microflora, new CABP treatments are needed. Antibiotic resistance is a complex, emerging problem globally with potentially devastating consequences for public health.

About Cempra, Inc.

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin has been successfully evaluated in two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and applications for approval for both intravenous and oral capsule formulations have been accepted for review by the FDA and the EMA. Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Fusidic acid is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure infections (ABSSSI) and is also in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com .

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: our and our strategic commercial partners' ability to obtain FDA and foreign regulatory approval of our product candidates, including solithromycin; our ability to commercialize and launch, whether on our own or with a strategic partner, any product candidate that receives regulatory approval; our ability to produce and sell any approved products and the price we are able to realize for those products; our ability to retain and hire necessary employees and to staff our operations appropriately; the unpredictability of the size of the markets for, and market acceptance of, any of our products, including solithromycin and fusidic acid; the costs, sources of funds, enrollment, timing, regulatory review and results of our studies and clinical trials and those of our strategic commercial partners; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our anticipated capital expenditures and our estimates regarding our capital requirements; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; our ability to compete in our industry; our dependence on the success of solithromycin and fusidic acid; innovation by our competitors; and our ability to stay abreast of and comply with new or modified laws and regulations that currently apply or become applicable to our business. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.

Contact: John Bluth Cempra, Inc. +1 984 209 4534 jbluth@cempra.com Investor Contact: Robert Uhl Westwicke Partners, LLC +1 858 356 5932 robert.uhl@westwicke.com Media Contact: Melyssa Weible Elixir Health PR +1 201 723 5805 mweible@elixirhealthpr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 86

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 72

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 7

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 123

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 108

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 99

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 143

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
DSFederal Takes On USDA NIFA Grants System Support Work

Updated Category News Views 0

A Quiet Contract With Real Operational Weight Grant paperwork rarely gets anybody’s pulse racing, yet a busted grants system can gum up research money from coast to coast in a hurry. DSFederal has won work supporting the U.S. Department of Agriculture’s National Institute of Food and Agriculture, or NIFA, through its Grants Management and Reporting System, known as...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 112

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Nike Locks In Chicago Marathon Partnership Through 2036 Deal

Updated Category News Views 13

Twenty-eight miles of pavement, training plans, and branded shoes are not a quarterly earnings release, but Nike just made a very long-term statement in Chicago. The company and the Bank of America Chicago Marathon have extended their partnership through 2036, preserving a relationship that began in 2008. For a brand rebuilding credibility with runners, that kind of...

Continue Reading

Top 5 Most Recently Viewed Articles

Bret Baier's Exclusive Interview with Trump on FOX Super Bowl Show

Updated Category News Views 296

Bret Baier's Exclusive Interview with President Donald Trump In a highly anticipated television event, Bret Baier, the chief political anchor for FOX News Channel (FNC), will engage in a significant one-on-one interview with President Donald Trump during the FOX Super Bowl LIX pregame show. This exclusive interview will air in the 3 PM/ET hour and is set to be a revealing...

Continue Reading
3D Systems Corporation Lawsuit Notification: What Investors Should Know

Updated Category News Views 169

3D Systems Corporation Lawsuit Overview The Gross Law Firm has issued a notice regarding an important class action lawsuit that involves shareholders of 3D Systems Corporation (NASDAQ: DDD). This legal action arises from allegations concerning misleading statements made by the company during a specific class period that could affect investors significantly. Understanding...

Continue Reading
5W PR Takes Charge of Marketing Strategies for Bedsure Pet

Updated Category News Views 191

5W PR Appointed as Agency of Record for Bedsure Pet Bedsure Pet, a leader in pet essentials, has recently welcomed 5W PR as their Agency of Record. This collaboration aims to elevate the brand's visibility and credibility in the competitive pet products market. About Bedsure Pet Products Bedsure Pet is celebrated for offering a wide range of high-quality pet products,...

Continue Reading
Itafos Enhances Financial Stability by Selling St George Shares

Updated Category News Views 155

Itafos Strengthens Financial Position Through Share Monetization HOUSTON, Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) has made headlines with its recent strategic move to partially monetize its equity interest in St George Mining Limited. This transaction, framed within the context of a larger corporate strategy, was initially announced following the sale of the Araxá...

Continue Reading
Hawkeye Invest AS Expands Stake in PCI Biotech Holding ASA

Updated Category News Views 343

Hawkeye Invest AS Enhances its Investment in PCI Biotech Holding ASA In a significant move, Hawkeye Invest AS, under the leadership of Øystein Barmen, has increased its stake in PCI Biotech Holding ASA by acquiring an additional 240,000 shares. This latest purchase has elevated their total ownership to 2,000,000 shares, representing a noteworthy 5.36% of the total shares...

Continue Reading